CN102608337A - 凝血酶原时间测定试剂盒及其制备方法 - Google Patents
凝血酶原时间测定试剂盒及其制备方法 Download PDFInfo
- Publication number
- CN102608337A CN102608337A CN2012100325841A CN201210032584A CN102608337A CN 102608337 A CN102608337 A CN 102608337A CN 2012100325841 A CN2012100325841 A CN 2012100325841A CN 201210032584 A CN201210032584 A CN 201210032584A CN 102608337 A CN102608337 A CN 102608337A
- Authority
- CN
- China
- Prior art keywords
- buffer solution
- solution system
- tissue factor
- prothrombin time
- recombinant human
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010094028 Prothrombin Proteins 0.000 title claims abstract description 31
- 102100027378 Prothrombin Human genes 0.000 title claims abstract description 31
- 229940039716 prothrombin Drugs 0.000 title claims abstract description 31
- 238000002360 preparation method Methods 0.000 title abstract description 13
- 238000012360 testing method Methods 0.000 title abstract description 8
- 108010000499 Thromboplastin Proteins 0.000 claims abstract description 42
- 102000002262 Thromboplastin Human genes 0.000 claims abstract description 42
- 241000283973 Oryctolagus cuniculus Species 0.000 claims abstract description 41
- 210000005013 brain tissue Anatomy 0.000 claims abstract description 29
- 238000000034 method Methods 0.000 claims abstract description 19
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract description 18
- 239000007788 liquid Substances 0.000 claims abstract description 11
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims abstract description 10
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 claims abstract description 9
- 239000011780 sodium chloride Substances 0.000 claims abstract description 9
- CFWRDBDJAOHXSH-SECBINFHSA-N 2-azaniumylethyl [(2r)-2,3-diacetyloxypropyl] phosphate Chemical compound CC(=O)OC[C@@H](OC(C)=O)COP(O)(=O)OCCN CFWRDBDJAOHXSH-SECBINFHSA-N 0.000 claims abstract description 7
- 239000007853 buffer solution Substances 0.000 claims description 76
- 101000635804 Homo sapiens Tissue factor Proteins 0.000 claims description 31
- 210000002381 plasma Anatomy 0.000 claims description 16
- 230000035945 sensitivity Effects 0.000 claims description 12
- 230000023555 blood coagulation Effects 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 8
- 235000008733 Citrus aurantifolia Nutrition 0.000 claims description 8
- 235000011941 Tilia x europaea Nutrition 0.000 claims description 8
- 235000013905 glycine and its sodium salt Nutrition 0.000 claims description 8
- 239000004571 lime Substances 0.000 claims description 8
- 238000004458 analytical method Methods 0.000 claims description 5
- 230000003139 buffering effect Effects 0.000 claims description 4
- 238000012856 packing Methods 0.000 claims description 4
- 238000003908 quality control method Methods 0.000 claims description 4
- 238000009777 vacuum freeze-drying Methods 0.000 claims description 4
- 239000003153 chemical reaction reagent Substances 0.000 abstract description 40
- 210000004556 brain Anatomy 0.000 abstract description 5
- 239000000843 powder Substances 0.000 abstract description 5
- PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 abstract 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 abstract 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 abstract 1
- 239000004471 Glycine Substances 0.000 abstract 1
- 206010022489 Insulin Resistance Diseases 0.000 abstract 1
- 229940098773 bovine serum albumin Drugs 0.000 abstract 1
- 239000001110 calcium chloride Substances 0.000 abstract 1
- 229910001628 calcium chloride Inorganic materials 0.000 abstract 1
- 230000007547 defect Effects 0.000 abstract 1
- 238000002474 experimental method Methods 0.000 description 8
- 239000003146 anticoagulant agent Substances 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 238000012544 monitoring process Methods 0.000 description 7
- 238000001514 detection method Methods 0.000 description 5
- 229940127219 anticoagulant drug Drugs 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 102000009123 Fibrin Human genes 0.000 description 3
- 108010073385 Fibrin Proteins 0.000 description 3
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 3
- 108010049003 Fibrinogen Proteins 0.000 description 3
- 102000008946 Fibrinogen Human genes 0.000 description 3
- 208000007536 Thrombosis Diseases 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 229950003499 fibrin Drugs 0.000 description 3
- 229940012952 fibrinogen Drugs 0.000 description 3
- 238000007710 freezing Methods 0.000 description 3
- 210000003709 heart valve Anatomy 0.000 description 3
- 230000002980 postoperative effect Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 230000005298 paramagnetic effect Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- PQMOXTJVIYEOQL-UHFFFAOYSA-N Cumarin Natural products CC(C)=CCC1=C(O)C(C(=O)C(C)CC)=C(O)C2=C1OC(=O)C=C2CCC PQMOXTJVIYEOQL-UHFFFAOYSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108010014172 Factor V Proteins 0.000 description 1
- 108010074860 Factor Xa Proteins 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 1
- FSOGIJPGPZWNGO-UHFFFAOYSA-N Meomammein Natural products CCC(C)C(=O)C1=C(O)C(CC=C(C)C)=C(O)C2=C1OC(=O)C=C2CCC FSOGIJPGPZWNGO-UHFFFAOYSA-N 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 208000035992 Postmortem Changes Diseases 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 201000000839 Vitamin K Deficiency Bleeding Diseases 0.000 description 1
- 206010047634 Vitamin K deficiency Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000003698 antivitamin K Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 208000015294 blood coagulation disease Diseases 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 208000031169 hemorrhagic disease Diseases 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 102000057593 human F8 Human genes 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000037323 metabolic rate Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 238000000275 quality assurance Methods 0.000 description 1
- 229940047431 recombinate Drugs 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 208000016794 vitamin K deficiency hemorrhagic disease Diseases 0.000 description 1
- 229940019333 vitamin k antagonists Drugs 0.000 description 1
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical class OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 1
Images
Landscapes
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
时间 | 本发明试剂 | 市售试剂 |
1天 | 12.1 | 12.2 |
2天 | 12.2 | 12.4 |
3天 | 12.3 | 13.6 |
4天 | 12.2 | 14.8 |
5天 | 12.5 | 18.1 |
6天 | 12.8 | 22.3 |
7天 | 13.7 | 25.5 |
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210032584.1A CN102608337B (zh) | 2011-04-22 | 2012-02-14 | 凝血酶原时间测定试剂盒及其制备方法 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201110101378.7 | 2011-04-22 | ||
CN201110101378 | 2011-04-22 | ||
CN201210032584.1A CN102608337B (zh) | 2011-04-22 | 2012-02-14 | 凝血酶原时间测定试剂盒及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102608337A true CN102608337A (zh) | 2012-07-25 |
CN102608337B CN102608337B (zh) | 2014-05-14 |
Family
ID=46525874
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201210032584.1A Active CN102608337B (zh) | 2011-04-22 | 2012-02-14 | 凝血酶原时间测定试剂盒及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102608337B (zh) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103376329A (zh) * | 2012-04-19 | 2013-10-30 | 蓬莱诺康药业有限公司 | 巴曲亭及其有效成份止血作用的表征方法 |
CN103852362A (zh) * | 2014-03-13 | 2014-06-11 | 皖南医学院 | 兔脑组织因子冻干制剂的制备方法 |
CN104991079A (zh) * | 2015-07-16 | 2015-10-21 | 青岛古高生物科技有限公司 | 一种凝血试剂用抗氧化剂 |
CN105277666A (zh) * | 2014-06-27 | 2016-01-27 | 中国人民解放军第三〇二医院 | 一种用于评价三七抗凝活性的生物效价检定方法 |
CN105368915A (zh) * | 2015-11-12 | 2016-03-02 | 武汉中太生物技术有限公司 | 凝血酶原时间测定试剂盒及其制备方法 |
CN105368916A (zh) * | 2015-11-12 | 2016-03-02 | 武汉景川诊断技术股份有限公司 | 一种凝血酶原时间测定试剂盒及其制备方法 |
CN106591267A (zh) * | 2017-01-04 | 2017-04-26 | 三诺生物传感股份有限公司 | 一种凝血活酶及其提取方法以及pt试剂 |
CN109975560A (zh) * | 2019-04-12 | 2019-07-05 | 深圳优迪生物技术有限公司 | 微流控凝血检测卡及凝血检测仪器 |
CN111638374A (zh) * | 2020-06-08 | 2020-09-08 | 深圳市国赛生物技术有限公司 | 一种用于测定凝血酶原时间的体外诊断试剂盒 |
CN112481355A (zh) * | 2020-11-16 | 2021-03-12 | 武汉市长立生物技术有限责任公司 | 液体型凝血酶原时间测定试剂盒及其制备方法 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110412001B (zh) * | 2019-08-01 | 2022-02-11 | 武汉塞力斯生物技术有限公司 | 一种动态监测凝血酶生成能力的试剂盒 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993007492A1 (en) * | 1991-10-04 | 1993-04-15 | Baxter Diagnostics Inc. | Preparation of prothrombin time reagents from recombinant human tissue factor and purified natural and synthetic phospholipids |
US6183979B1 (en) * | 1999-03-24 | 2001-02-06 | International Technidyne Corporation | Preparation of dried synthetic prothrombin time reagents |
CN1523358A (zh) * | 2002-11-05 | 2004-08-25 | ����ɨ������˾ | 一种基于组织因子的凝血酶原时间试剂的制备方法 |
CN1952169A (zh) * | 2005-10-18 | 2007-04-25 | 上海太阳生物技术有限公司 | 临床检验凝血酶原时间(pt)测定体外诊断试剂盒 |
EP1975622A1 (en) * | 2007-03-28 | 2008-10-01 | Sysmex Corporation | Reagent for measuring clotting time and method for stabilizing tissue factor |
CN101294163A (zh) * | 2007-04-23 | 2008-10-29 | 上海长岛生物技术有限公司 | 一种基于人重组凝血活酶的液体型pt试剂的制备方法 |
-
2012
- 2012-02-14 CN CN201210032584.1A patent/CN102608337B/zh active Active
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993007492A1 (en) * | 1991-10-04 | 1993-04-15 | Baxter Diagnostics Inc. | Preparation of prothrombin time reagents from recombinant human tissue factor and purified natural and synthetic phospholipids |
US5625036A (en) * | 1991-10-04 | 1997-04-29 | Dade International Inc. | Preparation of prothrombin time reagents from recombinant human tissue factor and purified natural and synthetic phospholipids |
US6183979B1 (en) * | 1999-03-24 | 2001-02-06 | International Technidyne Corporation | Preparation of dried synthetic prothrombin time reagents |
CN1523358A (zh) * | 2002-11-05 | 2004-08-25 | ����ɨ������˾ | 一种基于组织因子的凝血酶原时间试剂的制备方法 |
CN1952169A (zh) * | 2005-10-18 | 2007-04-25 | 上海太阳生物技术有限公司 | 临床检验凝血酶原时间(pt)测定体外诊断试剂盒 |
EP1975622A1 (en) * | 2007-03-28 | 2008-10-01 | Sysmex Corporation | Reagent for measuring clotting time and method for stabilizing tissue factor |
CN101294163A (zh) * | 2007-04-23 | 2008-10-29 | 上海长岛生物技术有限公司 | 一种基于人重组凝血活酶的液体型pt试剂的制备方法 |
Non-Patent Citations (4)
Title |
---|
ANNIE ROBERT等: "Prothrombin Time in Liver Failure: Time, Ratio, Activity Percentage, or International Normalized Ratio?", 《HEPATOLOGY》 * |
JUHA HORSTI等: "Poor Agreement among Prothrombin Time International Normalized Ratio Methods: Comparison of Seven Commercial Reagents", 《CLINICAL CHEMISTRY》 * |
张存山等: "凝血酶原时间测定方法和正常值", 《人民军医》 * |
徐涛: "组织凝血活素的研展和临床应用", 《脏器生化制药》 * |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103376329A (zh) * | 2012-04-19 | 2013-10-30 | 蓬莱诺康药业有限公司 | 巴曲亭及其有效成份止血作用的表征方法 |
CN103852362A (zh) * | 2014-03-13 | 2014-06-11 | 皖南医学院 | 兔脑组织因子冻干制剂的制备方法 |
CN103852362B (zh) * | 2014-03-13 | 2016-01-20 | 皖南医学院 | 冻干兔脑组织因子的制备方法 |
CN105277666A (zh) * | 2014-06-27 | 2016-01-27 | 中国人民解放军第三〇二医院 | 一种用于评价三七抗凝活性的生物效价检定方法 |
CN104991079A (zh) * | 2015-07-16 | 2015-10-21 | 青岛古高生物科技有限公司 | 一种凝血试剂用抗氧化剂 |
CN104991079B (zh) * | 2015-07-16 | 2016-04-06 | 青岛古高生物科技有限公司 | 一种凝血试剂用抗氧化剂 |
CN105368916A (zh) * | 2015-11-12 | 2016-03-02 | 武汉景川诊断技术股份有限公司 | 一种凝血酶原时间测定试剂盒及其制备方法 |
CN105368915A (zh) * | 2015-11-12 | 2016-03-02 | 武汉中太生物技术有限公司 | 凝血酶原时间测定试剂盒及其制备方法 |
CN105368915B (zh) * | 2015-11-12 | 2019-03-08 | 武汉中太生物技术有限公司 | 凝血酶原时间测定试剂盒及其制备方法 |
CN106591267A (zh) * | 2017-01-04 | 2017-04-26 | 三诺生物传感股份有限公司 | 一种凝血活酶及其提取方法以及pt试剂 |
CN106591267B (zh) * | 2017-01-04 | 2020-02-04 | 三诺生物传感股份有限公司 | 一种凝血活酶及其提取方法以及pt试剂 |
CN109975560A (zh) * | 2019-04-12 | 2019-07-05 | 深圳优迪生物技术有限公司 | 微流控凝血检测卡及凝血检测仪器 |
CN111638374A (zh) * | 2020-06-08 | 2020-09-08 | 深圳市国赛生物技术有限公司 | 一种用于测定凝血酶原时间的体外诊断试剂盒 |
CN112481355A (zh) * | 2020-11-16 | 2021-03-12 | 武汉市长立生物技术有限责任公司 | 液体型凝血酶原时间测定试剂盒及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN102608337B (zh) | 2014-05-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102608337B (zh) | 凝血酶原时间测定试剂盒及其制备方法 | |
Astrup et al. | The fibrin plate method for estimating fibrinolytic activity | |
US20190353674A1 (en) | Method for determining cause of the prolongation of blood coagulation time | |
JP5123496B2 (ja) | 血液凝固試験の標準化のための方法 | |
CN101221189A (zh) | 一种用于测定活化部分凝血活酶时间aptt的体外诊断试剂盒 | |
CN102690862B (zh) | 抗凝血酶ⅲ(at-ⅲ)测定试剂盒(发色底物法) | |
CN107748267B (zh) | 一种测定活化部分凝血活酶时间(aptt)的试剂盒 | |
CN104808006B (zh) | 一种糖化血红蛋白标准物质及其制备方法 | |
CN105368915B (zh) | 凝血酶原时间测定试剂盒及其制备方法 | |
CN104062243A (zh) | 一种FXa活性检测试剂及其制备方法和应用 | |
CN112481355B (zh) | 液体型凝血酶原时间测定试剂盒及其制备方法 | |
KR20140033422A (ko) | 루프스 안티코아귤란트 검출용 혈액 응고시간의 측정방법 | |
CN1952169A (zh) | 临床检验凝血酶原时间(pt)测定体外诊断试剂盒 | |
CN108613977A (zh) | 一种n末端脑钠肽前体检测试剂盒及其检测方法 | |
van den Besselaar | Accuracy, precision, and quality control for point-of-care testing of oral anticoagulation | |
CN106645665B (zh) | 一种凝血酶时间检测试剂 | |
CN105368916B (zh) | 一种凝血酶原时间测定试剂盒及其制备方法 | |
CN102692516A (zh) | 狼疮抗凝物筛选测定试剂盒(凝固法) | |
US8445287B2 (en) | Method and apparatus for determining anticoagulant therapy factors | |
Naghibi et al. | Effects of reagent and instrument on prothrombin times, activated partial thromboplastin times and patient/control ratios | |
CN106568765A (zh) | 用于抗凝血酶iii活性测定的凝血酶发色底物液、凝血酶水溶液、方法以及试剂盒 | |
EP1907866B1 (en) | Method and apparatus for determining anticoagulant therapy factors | |
CN106645751B (zh) | 一种纤维蛋白原含量检测试剂盒 | |
EP2546637B1 (en) | Method and apparatus for determining anticoagulant therapy factors | |
CN109073662A (zh) | 用于鉴定与抗磷脂综合征相关的狼疮抗凝物(la)的方法和试剂盒 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20130107 Address after: 430040, Jinshan Road, Dongxihu District, Hubei, Wuhan Province, 1310 Applicant after: WUHAN THALYS BIOLOGICAL TECHNOLOGY CO.,LTD. Address before: 430040, Jinshan Road, Dongxihu District, Hubei, Wuhan Province, 1310 Applicant before: WUHAN THALYS BIOLOGIC TECHNOLOGY Co.,Ltd. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Prothrombin time assay kit and preparation method thereof Effective date of registration: 20220823 Granted publication date: 20140514 Pledgee: Guanggu Branch of Wuhan Rural Commercial Bank Co.,Ltd. Pledgor: WUHAN THALYS BIOLOGICAL TECHNOLOGY CO.,LTD. Registration number: Y2022420000268 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20230825 Granted publication date: 20140514 Pledgee: Guanggu Branch of Wuhan Rural Commercial Bank Co.,Ltd. Pledgor: WUHAN THALYS BIOLOGICAL TECHNOLOGY CO.,LTD. Registration number: Y2022420000268 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Prothrombin time assay kit and its preparation method Effective date of registration: 20230830 Granted publication date: 20140514 Pledgee: Guanggu Branch of Wuhan Rural Commercial Bank Co.,Ltd. Pledgor: WUHAN THALYS BIOLOGICAL TECHNOLOGY CO.,LTD. Registration number: Y2023980054708 |